CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
- Positive results from the first large-animal study in January 2023
- Unique breast implants designed to regenerate breast tissue and provide safety advantages
- Potential to address safety issues in the breast implant market, including BIA-ALCL
- Use of proprietary plant-derived rhCollagen and other biomaterials
- Initiation of a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants
- None.
The regenerative breast implants market, part of the broader $2.6 billion breast implants industry, is on the cusp of a potential transformation. CollPlant Biotechnologies' initiation of a pre-clinical trial for 3D-bioprinted, regenerative breast implants could signal a significant shift in product offerings and competitive dynamics. With safety concerns such as BIA-ALCL affecting public perception and regulatory scrutiny, a successful entry of a safer, tissue-regenerating alternative could disrupt market leaders and alter market shares.
Investors should monitor the progression of these clinical trials closely as positive outcomes could lead to substantial market revaluation for CollPlant. However, the timeline until commercialization is notably extended, with pivotal studies and regulatory discussions pending. The market's response to this innovation will depend on clinical efficacy, safety profile and the ability to scale production while maintaining quality.
CollPlant's proprietary plant-derived rhCollagen presents a significant advancement in tissue engineering. The emphasis on regenerative capabilities and the reduced likelihood of an immune response could address a critical unmet need in postmastectomy reconstruction and cosmetic augmentation. The positive results from early large-animal studies suggest a promising trajectory, but the leap from pre-clinical to commercial success is fraught with scientific and regulatory hurdles.
Long-term, if the technology proves scalable and efficacious, it could redefine standards of care and potentially extend into other areas of regenerative medicine. Stakeholders should consider the implications of a successful product on the broader healthcare ecosystem, including impacts on surgical practices, patient outcomes and healthcare costs.
The financial implications for CollPlant and its investors hinge on the successful navigation of the clinical trial process and subsequent FDA discussions. Given the size of the breast implant market and the potential for a safer, innovative product, the upside for CollPlant could be substantial. However, investors must weigh this against the inherent risks of clinical trial outcomes, regulatory approval processes and the capital required to reach commercialization.
The cost of research and development in biotechnology is high and the time frame until revenue generation can be lengthy. While the market opportunity is significant, the current valuation of CollPlant will likely reflect both the potential future earnings and the risks associated with bringing a new medical product to market. Close attention to trial results and FDA feedback will be crucial for evaluating the investment's potential return.
- The current market for breast implants is estimated at
$2.6 billion - CollPlant expects the study to conclude by the first half of 2024
- CollPlant plans to use findings from this study and successive studies during 2024 for further optimization of the implant design towards a GLP preclinical pivotal study with commercial size implants
REHOVOT,
"We are very happy with the progress of our regenerative breast implants program thus far, and the initiation of this important study," said CollPlant's Chief Executive Officer, Yehiel Tal. "CollPlant's breast implants in development are unique in that they are designed to regenerate breast tissue as well as have inherent safety advantages. This would be paradigm-shifting in a market that has maintained such a large demand yet has seen increasing issues with safety over the last few decades. A primary goal of this study is to obtain data which would then support the optimization of the implant design and apply this design to a pivotal large-animal study that is intended to be the subject of discussions with the FDA."
In the
In January 2023, CollPlant announced positive results from its first large-animal study, which demonstrated progressive stages of tissue regeneration after three months, as highlighted by the formation of maturing connective tissue and neovascular networks within the implants, with no adverse events reported.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.
In 2021 CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com.
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Eran@collplant.com
Investors:
LifeSci Advisors
John Mullaly
jmullaly@lifesciadvisors.com
Photo: https://mma.prnewswire.com/media/2309446/CollPlant_breast_implants.jpg
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-begins-preclinical-trial-with-commercial-size-regenerative-breast-implants-302024360.html
SOURCE CollPlant
FAQ
What is the purpose of CollPlant Biotechnologies' (CLGN) pre-clinical trial for regenerative breast implants?
What are the potential advantages of CollPlant's breast implants?
What are the positive outcomes from the first large-animal study conducted by CollPlant?
What materials are used in CollPlant's breast implants?
What is the estimated market size for breast implants?
